CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with hormone receptor-positive breast cancer, prostate cancer, lung cancer, non-Hodgkin lymphoma and chronic lymphocytic leukemia, and multiple myeloma.
  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences. 
  • Recall ongoing clinical trials for select hematologic cancers and solid tumors, and as appropriate, refer patients for participation. 
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in individualizing therapy for patients with cancer. 
  • Educate patients with select hematologic cancers and solid tumors about the benefits and risks of novel therapeutic agents and strategies. 
  • Refine or validate existing cancer treatment algorithms, considering new datasets and the perspectives of tumor-specific clinical investigators. 
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a post-test, enables the participant to earn up to 6 (audio) and 5.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/FCS2024/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/FCS2024/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/FCS2024/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/FCS2024.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Sarah B Goldberg, MD, MPH
  Associate Professor of Medicine (Medical Oncology)
  Chief of Thoracic Oncology
  Co-Director of the Center for Thoracic Cancers
  Yale Cancer Center
  New Haven, Connecticut
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Regeneron Pharmaceuticals Inc, Summit Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Mirati Therapeutics Inc; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Kite, A Gilead Company, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Lilly, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeiGene Ltd, Roche Laboratories Inc.
  
  Sagar Lonial, MD
  Chair and Professor
  Department of Hematology and Medical Oncology
  Anne and Bernard Gray Family Chair in Cancer
  Chief Medical Officer
  Winship Cancer Institute
  Emory University School of Medicine
  Atlanta, Georgia
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis; Stock Options/Stock — Public Company: TG Therapeutics Inc.
  
  Joyce O’Shaughnessy, MD
  Celebrating Women Chair in Breast Cancer Research
  Baylor University Medical Center
  Chair, Breast Disease Committee
  Sarah Cannon Research Institute
  Dallas, Texas
  
  Advisory Committees and Consulting Agreements: Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Byondis, Caris Life Sciences, Daiichi Sankyo Inc, DAVA Oncology, Eisai Inc, Exact Sciences Corporation, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Mersana Therapeutics Inc, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Tempus, Veru Inc.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committees: Caribou Biosciences Inc, Immuneel Therapeutics; Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Janssen Biotech Inc, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: bluebird bio.
  
  Joshua K Sabari, MD
  Attending Physician
  Thoracic Medical Oncology
  Assistant Professor of Medicine
  NYU Langone Health
  Perlmutter Cancer Center
  New York, New York
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc.
  
  Matthew R Smith, MD, PhD
  Claire and John Bertucci Endowed Chair in Genitourinary Cancers
  Professor of Medicine
  Harvard Medical School
  Director, Genitourinary Malignancies Program
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committees and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Arvinas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.
  
  Sonali M Smith, MD
  Elwood V Jensen Professor of Medicine
  Chief, Section of Hematology/Oncology
  Co-Leader, Cancer Service Line
  Co-Director, Lymphoma Program
  The University of Chicago
  Chicago, Illinois
  
  Consulting Agreements: Genmab US Inc, Ono Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc; Contracted Research: Ipsen Biopharmaceuticals Inc; Nonrelevant Financial Relationships: Caris Life Sciences (spouse employment), Lymphoma Research Foundation.
  
  Sandy Srinivas, MD
  Professor of Oncology
  Clinical Research Leader, GU Oncology
  Stanford University
  Stanford, California
  
  Advisory Committees: Aveo Pharmaceuticals, Eisai Inc, Janssen Biotech Inc, Novartis, Seagen Inc; Contracted Research: Bristol Myers Squibb, Merck, Novartis, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc.
  
  Seth Wander, MD, PhD
  Assistant Professor of Medicine
  Harvard Medical School
  Attending Physician
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committees: Biovica International AB, Genentech, a member of the Roche Group, Hologic Inc, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foundation Medicine, Lilly, Novartis; Contracted Research: Genentech, a member of the Roche Group, Lilly, Nuvation Bio, Pfizer Inc, Regor Therapeutics Group, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Regor Therapeutics Group; Speakers Bureaus: Guardant Health, Lilly; Nonrelevant Financial Relationship: 2nd.MD.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from ADC Therapeutics, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, GSK, Hologic Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Legend Biotech, Lilly, Merck, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, and Stemline Therapeutics Inc.
  
  Release date: November 2024
  Expiration date: November 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.